

Medical Device Clinical Evaluation (MDCE)Working Group Update

National Medical Product Administration, China

September 23th, 2020

Work Item


16th MC meeting Approved NWIE to address some issues including:

- 1. The requirements for clinical evidence from new sources of clinical data.
- 2. Basing a PMCF study on clinical experiences.
- 3. What clinical issues are appropriate to investigate prior to marketing and what may be investigated post-market.
- 4. Update to align guidance to changes in other documents.

update

GHTF/SG5/N4:Post-Market Clinical Follow-Up Studies

Work plan & progress



Preparation

- Modify NWIE form.
- Literature reviews from 81 relative documents of all 10 jurisdictions.

Draft document

- 3 Rounds of discussion
- 11 Tele-conferences
- 5 Versions

Discussion	Comments	
1 st round	160	
2 nd round	65	
3 rd round	20	plus 120 editorial comments

Examples of proposed changes

1. What issues can be addressed via PMCF studies? change "Residual risks" to "Uncertainties".

- 2. Circumstances where a PMCF study may be indicated.
 - 9 examples describe the circumstances.
- 3. The use of information from PMCF studies.
 - 9 examples describe the utilization.

4. Elements of a PMCF study

design & implementation

5. New appendixes (informative)

Appendix A: Examples of clinical experience data sources

Appendix B: Considerations of using clinical experience data

Appendix C: Potential bias and control methods



Timeline

2020

Aug. Submit working draft to MC (milestone 1)

Sep. Woking draft to be considered during MC meeting

Sep. – Nov. Public consultation period

Nov. – Dec. Discuss the comments

2021

Jan. Finalize draft document

Feb. Submit final documents to MC

Mar. Final documents to be considered during MC meeting (milestone 2)

IMDRF MDCE WG(WD2)/Nx (formerly GHTF/SG5/N4:2010)



Working Draft

Title: Post-Market Clinical Follow-Up Studies

Authoring Group: Medical Device Clinical Evaluation Working Group

Endorsed by: IMDRF Management Committee

Date: 7 August, 2020 February 18, 2010

Dr. Larry Kelly, GHTF Chair

The document herein was produced by the Global Harmonization Task Force International Medical Device Regulators Forum, which is comprised of representatives from medical device regulatory agencies and the regulated industry. The document is intended to provide non-hinding guidance for use in the regulation of medical devices, and has been subject to consultation throughout its development. There are no restrictions of the reproduction, distribution or use of this document; however, incorporation of this document, in part or in whole, into any other document, or its translation into languages other than English, does not convey or represent an endorsement of any kind by the Global Harmonization Task Force International Medical Device Regulators Forum

Copyright © 2010 by the Global Harmonization Task Force 2020 by the International Medical Device Regulators Forum







Thank you